Hormonal contraception and venous thromboembolism

Background. New studies about the influence of hormonal contraception on the risk of venous thromboembolism (VTE) have been published. Aim. To evaluate new epidemiological data and to propose clinical consequences. Design. A literature survey. Methods. Studies assessing the risk of specific types of hormonal contraception were evaluated, compared and set into a clinical perspective. Results. The majority of newer studies have demonstrated a threefold increased risk of VTE in current users of medium‐ and low‐dose combined oral contraceptives (COCs) with norethisterone, levonorgestrel (LNG) or norgestimate compared with non‐users. The same studies have demonstrated a sixfold increased risk of VTE in users of combined pills with desogestrel, gestodene, drospirenone or cyproteroneacetate, and in users of the contraceptive vaginal ring, compared with non‐users. The rate ratio of VTE between users of COCs with newer progestogens compared with users of COCs with LNG was 1.5–2.8 in seven studies and 1.0 in two studies. Progestogen‐only contraception did not confer an increased risk of VTE in any study. The incidence rate of VTE in non‐pregnant women aged 15–49 years using non‐hormonal contraception is three per 10 000 years. Conclusions. For women starting on hormonal contraception, we recommend medium‐ or low‐dose combined pills with norethisterone, LNG or norgestimate as first‐choice preparations. For the many women who are users of COCs with newer progestogens, although the absolute risk of VTE is low, a change to combined pills with norethisterone, LNG or norgestimate may halve their risk of VTE. Finally, we recommend COCs with 20 μg estrogen combined with the older progestogens to be launched in the Scandinavian countries. Women at an increased risk of VTE should consider progestogen‐only contraception or non‐hormonal contraception.

[1]  F R Rosendaal,et al.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study , 2009, BMJ : British Medical Journal.

[2]  F. Rosendaal,et al.  Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives , 2012, Journal of thrombosis and haemostasis : JTH.

[3]  P. Vercellini,et al.  Noncontraceptive health benefits of combined oral contraception. , 2005, Human reproduction update.

[4]  S. Jick,et al.  Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data , 2011, BMJ : British Medical Journal.

[5]  Amanda J Lee,et al.  Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study , 2007, BMJ : British Medical Journal.

[6]  S. Kreiner,et al.  Oral contraceptives and venous thromboembolism: a five-year national case-control study. , 2002, Contraception.

[7]  Niels Keiding,et al.  Thrombotic stroke and myocardial infarction with hormonal contraception. , 2012, The New England journal of medicine.

[8]  G. Eklund,et al.  ORAL CONTRACEPTIVES AND THROMBOEMBOLIC DISEASE: EFFECTS OF LOWERING ŒSTROGEN CONTENT , 1980, The Lancet.

[9]  World Health Organization Collaborative Study of Cardiov Contarception.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study , 1995, The Lancet.

[10]  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1996 .

[11]  W. Spitzer,et al.  The differential risk of oral contraceptives: the impact of full exposure history. , 1999, Human reproduction.

[12]  M. Marmot,et al.  Effect on stroke of different progestagens in low oestrogen dose oral contraceptives , 1999, The Lancet.

[13]  T. Farley,et al.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. , 1995, Lancet.

[14]  L. Parkin,et al.  Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database , 2011, BMJ : British Medical Journal.

[15]  S. Thompson,et al.  Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations. , 1980, British medical journal.

[16]  G. Leydon,et al.  Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database. , 1999, Human reproduction.

[17]  J. Vandenbroucke,et al.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen , 1995, The Lancet.

[18]  M. Vessey,et al.  Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004 , 2006, British Journal of Cancer.

[19]  A. Assmann,et al.  Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study , 2010, Journal of Family Planning and Reproductive Health Care.

[20]  R. Farmer,et al.  Population-based study of risk of venous thromboembolism associated with various oral contraceptives , 1997, The Lancet.

[21]  H. Jick,et al.  Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components , 1995, The Lancet.

[22]  W. Inman,et al.  Thromboembolic Disease and the Steroidal Content of Oral Contraceptives. A Report to the Committee on Safety of Drugs , 1970, British medical journal.

[23]  E. Løkkegaard,et al.  Hormonal contraception and risk of venous thromboembolism: national follow-up study , 2009, BMJ : British Medical Journal.

[24]  W. Spitzer,et al.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study , 1996, BMJ.

[25]  C. Paul,et al.  Oral contraceptives and fatal pulmonary embolism , 2000, The Lancet.

[26]  E. Løkkegaard,et al.  Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 , 2012, BMJ : British Medical Journal.

[27]  F. Rosendaal,et al.  Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate , 2004, Journal of thrombosis and haemostasis : JTH.

[28]  W. Spitzer,et al.  Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Transnational Research Group on Oral Contraceptives and the Health of Young Women. , 1998, Contraception.

[29]  K. Heinemann,et al.  Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. , 2014, Contraception.

[30]  L. Heinemann,et al.  The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. , 2007, Contraception.

[31]  J. Vandenbroucke,et al.  Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. , 1999, Archives of internal medicine.

[32]  E. Løkkegaard,et al.  Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9 , 2011, BMJ : British Medical Journal.

[33]  I. Persson,et al.  Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? , 2002, Acta obstetricia et gynecologica Scandinavica.

[34]  N. Gronich,et al.  Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study , 2011, Canadian Medical Association Journal.

[35]  S. Kreiner,et al.  Contraceptives and cerebral thrombosis: a five-year national case-control study. , 2002, Contraception.